Shire’s CEO Flemming Ornskov has hailed the launch of ophthalmology drug Xiidra ... call about Xiidra, a blockbuster hopeful that Shire stuck with despite a rejection in dry eye disease by ...

Novartis paid Takeda $3.4 billion for its FDA-approved dry eye drug Xiidra during the Japanese ... FDA approval of a phase 3 trial for eye drops containing tivanisiran, in dry eye disease associat ...